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Cost of dabigatran for atrial fibrillation
Cost effective in patients at high risk of stroke, unless INR is well controlled
Brian F Gage associate professor of medicine
Division of General Medical Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
Because atrial fibrillation is associated with advanced age and
obesity,itsprevalenceisincreasingworldwide.
1Newtreatments
such as ablation and left atrial occlusion may reduce the need
for anticoagulants in highly selected patients with atrial
fibrillation, but overall the use of anticoagulants will increase
in the foreseeable future. In the linked study (doi:10.1136/bmj.
d6333), Pink and colleagues assess the incremental costs and
benefits of dabigatran etexilate versus warfarin in patients with
non-valvular atrial fibrillation.
2
Until recently, warfarin and related vitamin K inhibitors have
been the only oral anticoagulants available. Warfarin is cheap
and effective, but it doubles the risk of haemorrhage, requires
carefulmonitoring,andhasmanydruginteractions.
3Compared
with warfarin, dabigatran has a wide therapeutic index, so no
monitoring or dose adjustment is needed (except in patients
with renal disease). Dabigatran works by inhibiting thrombin
directly, so its onset of action is rapid, unlike warfarin. To date,
dabigatranistheonlyneworalanticoagulantapprovedforatrial
fibrillation in several countries, including the United States.
Thus, dabigatran has the potential to be widely prescribed.
The potential economic consequences of widespread use of
dabigatran rather than warfarin are profound. For example, on
thebasisofPinkandcolleagues’data,ifalloftheapproximately
760 000 British patients with atrial fibrillation took dabigatran
(at£919.80(€1051;$1471)/year),thedrugcostwouldbe£700m
each year, but expenditures related to stroke and warfarin
monitoring would shrink. Given the potential financial effects
of dabigatran, the cost effectiveness analysis by Pink and
colleagues is timely and relevant.
2
TheauthorsuseaMarkovdecisionanalyticalmodeltodiscount
future events, to extrapolate from the two year RE-LY
(Randomized Evaluation of Long-Term Anticoagulation
Therapy) trial,
4 and they compare various health states using a
well accepted metric, quality adjusted life year (QALY). In the
base case, they calculate an incremental cost effectiveness of
£23082perQALY.TheadvantageofQALYsisthatthismetric
provides a common currency to account for complications of
atrial fibrillation and its prophylaxis. Clinicians may feel
uncomfortable extrapolating from a two year trial to a lifetime
horizon,butnolongtermdataareavailablefordabigatran.This
extrapolation is therefore needed for Pink and colleagues to
calculate the downstream consequences of stroke and stroke
prophylaxis.
Although stroke is the most feared consequence of atrial
fibrillation,preventionofstrokealsohasseriousrisks.Themost
important risk of prophylaxis is haemorrhage, especially
intracranial haemorrhage, which is lower for treatment with
dabigatran than with warfarin. In RE-LY, rates of intracerebral
haemorrhage (per 100 patient years) were 0.30 with dabigatran
150 mg twice daily and 0.74 with warfarin.
4 By explicitly
incorporating intracranial haemorrhage into their model, Pink
and colleagues captured the treatment specific rates of
intracranial haemorrhage and the clinical consequences.
Although intracranial haemorrhage is the most important risk
of any anticoagulant, other risks need to be considered.
Dabigatrancanalsocausebleedingatothersitesanddyspepsia.
Pink and colleagues accounted for the cost and utility
decrementsofbleedsbymodellingthemexplicitly:theyestimate
the cost of a major bleed as £1685 and the disutility as 0.1385
forone12thofayear—equivalenttoabouta0.01lossinQALY.
Fordyspepsia,theymodelledthecostoftreatmentwithaproton
pump inhibitor but did not explicitly account for the transient
utilitydecrementofdyspepsia.However,theeffectofdabigatran
induced dyspepsia on quality adjusted survival was much less
than 0.01 QALY in another model
5—not enough to alter cost
effectiveness significantly. Besides dyspepsia, RE-LY initially
reported an increased risk of myocardial infarction with
dabigatran,
4 but a reanalysis found that this trend was not
statisticallysignificant.Pinkandcolleagueschosetoincorporate
an increased risk of myocardial infarction into their model.
Whether this inclusion improves accuracy depends on whether
the lower rate of myocardial infarction with warfarin is a real
effect, which seems likely.
6 In summary, Pink and colleagues’
modelincorporatestherelevanthealthstatesneededtoestimate
cost effectiveness accurately.
To be valid, the decision model also needs to quantify risks,
costs, and utilities accurately. When these parameters were
compared with those from other studies (table⇓), Pink and
colleagues’ results were similar. Although the baseline stroke
rate in Pink and colleagues’ study is slightly higher than in the
comparator studies, all four studies examined a range of stroke
rates and stratified their results appropriately.
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EDITORIALSThese studies found that dabigatran was likely to be cost
effective for patients at high risk of stroke (Congestive heart
failure,Hypertension,Age≥75years,Diabetesmellitus,previous
Stroke/transientischaemicattack(CHADS2)scoreof3ormore),
unless international normalised ratio (INR) control was
excellent. For example, at a CHADS2 score of 3, Pink and
colleagues calculated a cost of £15 895 per QALY for centres
with average INR control. In contrast, all studies found that the
costperQALYgainedwashighinpatientsatlowriskofstroke.
In practice, clinicians should consider additional factors when
choosing treatment, such as patient preference and adherence.
For patients with a strong aversion to INR monitoring,
dabigatran will be more cost effective than in typical patients.
In contrast, for patients with poor adherence to treatment,
dabigatran will be less cost effective because it has a shorter
half life than warfarin.
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Table 1| Comparison of key parameters in published dabigatran and warfarin cost effectiveness studies
Study Key parameters
Sorensen et al
8 Freeman et al
7 Shah and Gage
5 Pink et al
3
69 65 70 67 Age at start (years)
Stroke risk:
0.88 1.20 1.19 1.38 Warfarin*
0.68 0.92 0.90 0.84 Dabigatran (150 mg)*
Haemorrhage risk:
3.06 4.10 3.36 3.31 Warfarin*†
2.69 3.41 3.12 3.04 Dabigatran (150 mg)*†
Utility:
1.0 0.994 0.994 0.998 Dabigatran
1.0 0.987 0.987 0.987 Warfarin
$C1168 $4745 $3284 £919.80 Cost of dabigatran (per year)‡
*For CHADS2 (Congestive heart failure, Hypertension, Age≥75 years, Diabetes mellitus, previous Stroke/transient ischaemic attack) score=2 or base-case
(depending on study) with rates per 100 patient years.
†Haemorrhage rates are for major bleeds, including intracranial haemorrhages.
‡£1=$1.6=$C1.6.
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